norfloxacin has been researched along with Infections, Staphylococcal in 72 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of a 5-day course of treatment with the new oral penem agent ritipenem acoxil (500 mg three times daily) or with norfloxacin (200 mg twice daily) were assessed in a double-blind study of women with uncomplicated cystitis." | 9.08 | Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. ( , 1995) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 9.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "Studies on a combination therapy of fosfomycin (FOM) and norfloxacin (NFLX) against chronic otitis media were performed, and the following results were obtained." | 7.70 | [Combination effect of fosfomycin otic solution and norfloxacin against chronic otitis media]. ( Uno, Y, 1999) |
| "We present three cases of norfloxacin deposits after treatment of bacterial keratitis." | 7.69 | Deposits of topical norfloxacin in the treatment of bacterial keratitis. ( Benitez del Castillo, JM; Castillo, A; Diaz-Valle, D; Garcia-Sanchez, J; Sayagues, O; Toledano, N, 1997) |
| "Norfloxacin (NFLX), a new quinolone antibiotic agent, was evaluated for its efficacy in experimental osteomyelitis in rabbits." | 7.68 | [Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits]. ( Aijima, H; Kaetsu, M; Okada, J, 1992) |
| "treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole." | 6.66 | Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study. ( Norrby, SR; Rylander, M; Svärd, R, 1987) |
| "Pefloxacin (Pef) is a new quinolone which has been shown to have good in-vitro activity against Staphylococcus aureus, and to reach high tissue concentrations." | 5.27 | Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses. ( Bouanchaud, DH; Huet, Y; Rolin, O, 1986) |
| "The efficacy and safety of a 5-day course of treatment with the new oral penem agent ritipenem acoxil (500 mg three times daily) or with norfloxacin (200 mg twice daily) were assessed in a double-blind study of women with uncomplicated cystitis." | 5.08 | Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. ( , 1995) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 5.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "Studies on a combination therapy of fosfomycin (FOM) and norfloxacin (NFLX) against chronic otitis media were performed, and the following results were obtained." | 3.70 | [Combination effect of fosfomycin otic solution and norfloxacin against chronic otitis media]. ( Uno, Y, 1999) |
| "We present three cases of norfloxacin deposits after treatment of bacterial keratitis." | 3.69 | Deposits of topical norfloxacin in the treatment of bacterial keratitis. ( Benitez del Castillo, JM; Castillo, A; Diaz-Valle, D; Garcia-Sanchez, J; Sayagues, O; Toledano, N, 1997) |
| "Norfloxacin (NFLX), a new quinolone antibiotic agent, was evaluated for its efficacy in experimental osteomyelitis in rabbits." | 3.68 | [Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits]. ( Aijima, H; Kaetsu, M; Okada, J, 1992) |
| "The effect of a single day treatment with 600 mg norfloxacin 600 mg ofloxacin or 1,920 mg trimethoprim-sulfamethoxazol was determined on 114 patients with acute cystitis." | 3.67 | [Single day treatment in acute cystitis]. ( Kawaguchi, K; Yamaguchi, K, 1988) |
| "Ofloxacin, a new pyridone-carboxylic acid derivative, was evaluated in descending nephritis and subcutaneous abscess models with Staphylococcus aureus in mice in comparison with norfloxacin." | 3.67 | Chemotherapeutic efficacy of ofloxacin on renal and subcutaneous infection models with Staphylococcus aureus in mice. ( Fujimoto, T; Katami, K; Osada, Y; Sato, M; Tachizawa, H; Tsumura, M; Une, T, 1986) |
| "treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole." | 2.66 | Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study. ( Norrby, SR; Rylander, M; Svärd, R, 1987) |
| "Diosgenin is a naturally occurring steroidal saponin that has demonstrated several pharmacological properties." | 1.72 | Evaluation of the antibacterial and inhibitory activity of NorA and MepA efflux pumps from Staphylococcus aureus by diosgenin. ( Araújo, NJS; Coutinho, HDM; da Silva, ARP; de Freitas, TS; de Sousa, EO; de Vasconcelos, JEL; do Socorro Costa, M; Filho, JMB; Maia, FPA; Pereira Junior, FN; Pinheiro, JCA; Tavares, JF, 2022) |
| "Feline otitis externa is a dermatological disorder with a multifactorial complex etiology." | 1.62 | Otodectic and bacterial etiology of feline otitis externa in Tripoli, Libya. ( Altaeb, AA; Bennour, EM; Duro, EM; Ellraiss, OM; Elmishri, RA; Hiblu, MA; Karim, ES, 2021) |
| "Gentamicin was the most efficacious agent inhibiting 78." | 1.48 | Frequency of enterotoxins, toxic shock syndrome toxin-1, and biofilm formation genes in Staphylococcus aureus isolates from cows with mastitis in the Northeast of Brazil. ( Andrade, GI; Belo, NO; Carvalho, IA; Costa, EA; Costa, FN; Pereira, LS; Santos, RL, 2018) |
| "Norfloxacin antibiotic was loaded into cross-linked poly(2-hydroxyethyl methacrylate) (pHEMA) gels, which were subsequently surface-modified with octadecyl isocyanate to produce a hydrophobic rate-limiting barrier controlling norfloxacin release." | 1.35 | Sustained release of antibiotic from poly(2-hydroxyethyl methacrylate) to prevent blinding infections after cataract surgery. ( Anderson, EM; Bryers, JD; Garty, S; Ma, H; Noble, ML; Ratner, BD; Shen, TT, 2009) |
| "Norfloxacin was marginally bound to serum protein." | 1.30 | Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ( Gips, M; Soback, S, 1999) |
| "Levofloxacin was the most potent fluoroquinolone against both strains and its activity was not significantly affected by combination with omeprazole." | 1.30 | The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. ( Aeschlimann, JR; Kaatz, GW; Rybak, MJ, 1999) |
| "Pefloxacin (Pef) is a new quinolone which has been shown to have good in-vitro activity against Staphylococcus aureus, and to reach high tissue concentrations." | 1.27 | Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses. ( Bouanchaud, DH; Huet, Y; Rolin, O, 1986) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| "Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1)." | 1.27 | [Pefloxacin: clinical experience]. ( Bertrand, A; Janbon, F; Jonquet, O; Jourdan, J; Santoni, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (27.78) | 18.7374 |
| 1990's | 21 (29.17) | 18.2507 |
| 2000's | 6 (8.33) | 29.6817 |
| 2010's | 14 (19.44) | 24.3611 |
| 2020's | 11 (15.28) | 2.80 |
| Authors | Studies |
|---|---|
| de Souza, NJ | 1 |
| Gupte, SV | 1 |
| Deshpande, PK | 1 |
| Desai, VN | 1 |
| Bhawsar, SB | 1 |
| Yeole, RD | 1 |
| Shukla, MC | 1 |
| Strahilevitz, J | 1 |
| Hooper, DC | 1 |
| Bozdogan, B | 1 |
| Appelbaum, PC | 1 |
| Jacobs, MR | 1 |
| Shetty, N | 1 |
| Patel, MV | 1 |
| Jha, R | 1 |
| Khorakiwala, HF | 1 |
| Zhi, C | 2 |
| Long, ZY | 2 |
| Manikowski, A | 2 |
| Brown, NC | 2 |
| Tarantino, PM | 2 |
| Holm, K | 1 |
| Dix, EJ | 2 |
| Wright, GE | 2 |
| Foster, KA | 2 |
| Butler, MM | 2 |
| LaMarr, WA | 2 |
| Skow, DJ | 1 |
| Motorina, I | 2 |
| Lamothe, S | 2 |
| Storer, R | 2 |
| Comstock, J | 1 |
| Xu, WC | 1 |
| Holm, KA | 1 |
| Barnes, MH | 1 |
| Bachand, B | 1 |
| Bethell, R | 1 |
| Cadilhac, C | 1 |
| Charron, S | 1 |
| DeMarco, CE | 1 |
| Cushing, LA | 1 |
| Frempong-Manso, E | 1 |
| Seo, SM | 1 |
| Jaravaza, TA | 1 |
| Kaatz, GW | 4 |
| Fontaine, F | 1 |
| Héquet, A | 1 |
| Voisin-Chiret, AS | 1 |
| Bouillon, A | 1 |
| Lesnard, A | 1 |
| Cresteil, T | 1 |
| Jolivalt, C | 1 |
| Rault, S | 1 |
| Lin, S | 1 |
| Koh, JJ | 1 |
| Aung, TT | 1 |
| Lim, F | 1 |
| Li, J | 1 |
| Zou, H | 1 |
| Wang, L | 1 |
| Lakshminarayanan, R | 1 |
| Verma, C | 1 |
| Wang, Y | 1 |
| Tan, DT | 1 |
| Cao, D | 1 |
| Beuerman, RW | 1 |
| Ren, L | 1 |
| Liu, S | 1 |
| Tareq, FS | 1 |
| Hasan, CM | 1 |
| Rahman, MM | 1 |
| Hanafi, MMM | 1 |
| Colombi Ciacchi, L | 1 |
| Michaelis, M | 1 |
| Harder, T | 1 |
| Tebben, J | 1 |
| Islam, MT | 1 |
| Spiteller, P | 1 |
| Zha, GF | 1 |
| Wang, SM | 1 |
| Rakesh, KP | 1 |
| Bukhari, SNA | 1 |
| Manukumar, HM | 1 |
| Vivek, HK | 1 |
| Mallesha, N | 1 |
| Qin, HL | 1 |
| Yu, JH | 1 |
| Xu, XF | 1 |
| Hou, W | 1 |
| Meng, Y | 1 |
| Huang, MY | 1 |
| Lin, J | 1 |
| Chen, WM | 1 |
| Anafo, RB | 1 |
| Atiase, Y | 1 |
| Kotey, FCN | 1 |
| Dayie, NTKD | 1 |
| Tetteh-Quarcoo, PB | 1 |
| Duodu, S | 1 |
| Osei, MM | 1 |
| Alzahrani, KJ | 1 |
| Donkor, ES | 1 |
| Mahey, N | 1 |
| Tambat, R | 1 |
| Chandal, N | 1 |
| Verma, DK | 1 |
| Thakur, KG | 1 |
| Nandanwar, H | 1 |
| Xavier, MR | 1 |
| Freitas, TS | 2 |
| Pereira, RLS | 2 |
| Marinho, EM | 1 |
| Bandeira, PN | 2 |
| de Sousa, AP | 1 |
| Oliveira, LS | 1 |
| Bezerra, LL | 1 |
| Neto, JBA | 1 |
| Silva, MMC | 1 |
| Cruz, BG | 1 |
| Rocha, JE | 2 |
| Barbosa, CRS | 1 |
| da Silva, AW | 1 |
| de Menezes, JESA | 1 |
| Coutinho, HDM | 4 |
| Marinho, MM | 2 |
| Marinho, ES | 2 |
| Dos Santos, HS | 2 |
| Teixeira, AMR | 2 |
| de Freitas, TS | 2 |
| Xavier, JC | 1 |
| Pereira Junior, FN | 2 |
| Nogueira, CES | 1 |
| Rodrigues, LG | 1 |
| de Lacerda, BCGV | 1 |
| de Andrade, EM | 1 |
| do Socorro Costa, M | 1 |
| da Silva, ARP | 1 |
| Araújo, NJS | 1 |
| Filho, JMB | 1 |
| Tavares, JF | 1 |
| de Sousa, EO | 1 |
| Maia, FPA | 1 |
| de Vasconcelos, JEL | 1 |
| Pinheiro, JCA | 1 |
| Cai, D | 1 |
| Yang, Y | 1 |
| Lu, J | 1 |
| Yuan, Z | 1 |
| Zhang, Y | 1 |
| Yang, X | 1 |
| Huang, X | 1 |
| Li, T | 1 |
| Tian, X | 1 |
| Xu, B | 1 |
| Wang, P | 1 |
| Lei, H | 1 |
| Lima Junior, PS | 1 |
| Nascimento, HJL | 1 |
| Nascimento de Sousa, J | 1 |
| Araújo de Alcântara Oliveira, F | 1 |
| Maria Duarte Lemos, G | 1 |
| de Andrade Ferreira Barreto, J | 1 |
| Kenned Silva Moura, A | 1 |
| Haydée Lima Ferreira, J | 1 |
| das Graças Lopes Citó, AM | 1 |
| de Oliveira, MM | 1 |
| Emidio Sampaio Nogueira, C | 1 |
| Douglas Melo Coutinho, H | 1 |
| Medeiros Barreto, H | 1 |
| Martin, ALAR | 1 |
| De Menezes, IRA | 1 |
| Sousa, AK | 1 |
| Farias, PAM | 1 |
| Dos Santos, FAV | 1 |
| Figueredo, FG | 1 |
| Ribeiro-Filho, J | 1 |
| Carvalho, DT | 1 |
| Fonteles, MMF | 1 |
| Sun, ZL | 1 |
| Sun, SC | 1 |
| He, JM | 1 |
| Lan, JE | 1 |
| Gibbons, S | 1 |
| Mu, Q | 1 |
| Hiblu, MA | 1 |
| Ellraiss, OM | 1 |
| Karim, ES | 1 |
| Elmishri, RA | 1 |
| Duro, EM | 1 |
| Altaeb, AA | 1 |
| Bennour, EM | 1 |
| Gupta, P | 1 |
| Patel, DK | 1 |
| Gupta, VK | 2 |
| Pal, A | 2 |
| Tandon, S | 1 |
| Darokar, MP | 2 |
| Lowrence, RC | 1 |
| Ramakrishnan, A | 1 |
| Sundaramoorthy, NS | 1 |
| Shyam, A | 1 |
| Mohan, V | 1 |
| Subbarao, HMV | 1 |
| Ulaganathan, V | 1 |
| Raman, T | 1 |
| Solomon, A | 1 |
| Nagarajan, S | 1 |
| Costa, FN | 1 |
| Belo, NO | 1 |
| Costa, EA | 1 |
| Andrade, GI | 1 |
| Pereira, LS | 1 |
| Carvalho, IA | 1 |
| Santos, RL | 1 |
| Silva, SWC | 1 |
| Monção, NBN | 1 |
| Araújo, BQ | 1 |
| Arcanjo, DDR | 1 |
| Ferreira, JHL | 1 |
| Lima Neto, JS | 1 |
| Citó, AMGL | 1 |
| de Siqueira Júnior, JP | 1 |
| Barreto, HM | 1 |
| Sinha, S | 1 |
| Kumar, P | 1 |
| Kumar, R | 1 |
| Joshi, R | 1 |
| Guo, Y | 1 |
| Xu, T | 1 |
| Bao, C | 1 |
| Liu, Z | 1 |
| Fan, J | 1 |
| Yang, R | 1 |
| Qin, S | 1 |
| Matias, EF | 1 |
| Santos, KK | 1 |
| Falcão-Silva, VS | 1 |
| Siqueira-Junior, JP | 1 |
| Costa, JG | 1 |
| Coutinho, HD | 1 |
| Azad, CS | 1 |
| Bhunia, SS | 1 |
| Krishna, A | 1 |
| Shukla, PK | 1 |
| Saxena, AK | 1 |
| Bert, F | 1 |
| Leflon-Guibout, V | 1 |
| Le Grand, J | 1 |
| Bourdon, N | 1 |
| Nicolas-Chanoine, MH | 1 |
| Anderson, EM | 1 |
| Noble, ML | 1 |
| Garty, S | 1 |
| Ma, H | 1 |
| Bryers, JD | 1 |
| Shen, TT | 1 |
| Ratner, BD | 1 |
| Filocamo, A | 1 |
| Bisignano, C | 1 |
| D'Arrigo, M | 1 |
| Ginestra, G | 1 |
| Mandalari, G | 1 |
| Galati, EM | 1 |
| González-Chomón, C | 1 |
| Braga, ME | 1 |
| de Sousa, HC | 1 |
| Concheiro, A | 1 |
| Alvarez-Lorenzo, C | 1 |
| Allemandi, DA | 1 |
| Alovero, FL | 1 |
| Manzo, RH | 1 |
| Hori, S | 1 |
| Ohshita, Y | 1 |
| Utsui, Y | 1 |
| Hiramatsu, K | 1 |
| Tankovic, J | 1 |
| Desplaces, N | 1 |
| Duval, J | 1 |
| Courvalin, P | 1 |
| Cogollos, R | 1 |
| Alós, JI | 1 |
| Gómez-Garcés, JL | 1 |
| Bow, EJ | 1 |
| Mandell, LA | 1 |
| Louie, TJ | 1 |
| Feld, R | 1 |
| Palmer, M | 1 |
| Zee, B | 1 |
| Pater, J | 1 |
| Aguilar, L | 1 |
| Balcabao, IP | 1 |
| Salvá, P | 1 |
| Martín, M | 1 |
| Costa, J | 1 |
| Prieto, J | 1 |
| Dal-ré, R | 1 |
| Castillo, A | 1 |
| Benitez del Castillo, JM | 1 |
| Toledano, N | 1 |
| Diaz-Valle, D | 1 |
| Sayagues, O | 1 |
| Garcia-Sanchez, J | 1 |
| Martino, R | 1 |
| Subira, M | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Sureda, A | 1 |
| Domingo-Albós, A | 1 |
| Pericas, R | 1 |
| Brunet, S | 1 |
| Aeschlimann, JR | 2 |
| Dresser, LD | 1 |
| Rybak, MJ | 2 |
| Uno, Y | 1 |
| Gips, M | 1 |
| Soback, S | 2 |
| Li, XH | 1 |
| Tian, ZM | 1 |
| Miao, H | 1 |
| Yu, LX | 1 |
| Guo, HY | 1 |
| Brodsky, A | 1 |
| Melero, M | 1 |
| Vay, C | 1 |
| Okada, J | 1 |
| Kaetsu, M | 1 |
| Aijima, H | 1 |
| Saginur, R | 1 |
| Nicolle, LE | 1 |
| Huber-Spitzy, V | 1 |
| Baumgartner, I | 1 |
| Arocker-Mettinger, E | 1 |
| Schiffbänker, M | 1 |
| Georgiew, L | 1 |
| Grabner, G | 1 |
| Shah, PM | 3 |
| Yoshida, S | 1 |
| Kojima, T | 1 |
| Inoue, M | 1 |
| Mitsuhashi, S | 1 |
| Ziv, G | 1 |
| Winkler, M | 1 |
| Saran, A | 1 |
| Moran, DB | 1 |
| Ziegler, CB | 1 |
| Dunne, TS | 1 |
| Kuck, NA | 1 |
| Lin, YI | 1 |
| Prieur, B | 1 |
| Di Menza, C | 1 |
| Charlot, J | 1 |
| Klastersky, J | 1 |
| Van der Auwera, P | 1 |
| Rolin, O | 1 |
| Huet, Y | 1 |
| Bouanchaud, DH | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Yamaguchi, K | 1 |
| Kawaguchi, K | 1 |
| Schmeiser, T | 1 |
| Kurrle, E | 1 |
| Arnold, R | 1 |
| Wiesneth, M | 1 |
| Bunjes, D | 1 |
| Hertenstein, B | 1 |
| Kern, W | 1 |
| Heit, W | 1 |
| Heimpel, H | 1 |
| Michéa-Hamzehpour, M | 1 |
| Pechère, JC | 1 |
| Marchou, B | 1 |
| Auckenthaler, R | 1 |
| Esko, E | 1 |
| Renkonen, OV | 1 |
| Bayer, AS | 1 |
| Greenberg, DP | 1 |
| Yih, J | 1 |
| Thauvin, C | 1 |
| Lemeland, JF | 1 |
| Humbert, G | 1 |
| Fillastre, JP | 1 |
| Denis, F | 1 |
| Mounier, M | 1 |
| Adenis, JP | 1 |
| Rylander, M | 1 |
| Norrby, SR | 1 |
| Svärd, R | 1 |
| Boland, DM | 1 |
| van Gestel, WC | 1 |
| MacLaren, DM | 1 |
| de Jong, D | 1 |
| Sheikh, MA | 1 |
| Naqvi, SA | 1 |
| Fujimoto, T | 1 |
| Sato, M | 1 |
| Katami, K | 1 |
| Osada, Y | 1 |
| Tsumura, M | 1 |
| Tachizawa, H | 1 |
| Une, T | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Modak, S | 1 |
| Fox, CL | 1 |
| Babu, SC | 1 |
| Sampath, L | 1 |
| Clauss, RH | 1 |
| Stahl, WM | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Jourdan, J | 1 |
| Jonquet, O | 1 |
| Santoni, A | 1 |
2 reviews available for norfloxacin and Infections, Staphylococcal
| Article | Year |
|---|---|
[Emergence of vancomycin-dependent enterococci following glycopeptide therapy: case report and review].
Topics: Bacterial Proteins; Bacteriuria; Carbon-Oxygen Ligases; Cecal Diseases; Ceftriaxone; Citrobacter fre | 2009 |
Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Therapy, Combination; Glycopeptides; Im | 1986 |
7 trials available for norfloxacin and Infections, Staphylococcal
| Article | Year |
|---|---|
Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteriuria; Cystitis; Data Interpretation, Statisti | 1995 |
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Bacteremia; Colony Count, Microbial; Fema | 1996 |
Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.
Topics: Adult; Anti-Infective Agents; Bacteriuria; Cross-Over Studies; Escherichia coli Infections; Fluoroqu | 1996 |
Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration | 1992 |
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Escherichia | 1987 |
Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit.
Topics: Bacterial Infections; Clinical Trials as Topic; Critical Care; Drug Resistance, Microbial; Humans; N | 1987 |
63 other studies available for norfloxacin and Infections, Staphylococcal
| Article | Year |
|---|---|
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resi | 2005 |
Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils.
Topics: Aniline Compounds; Animals; Anti-Bacterial Agents; DNA Polymerase III; Gram-Positive Bacteria; Mice; | 2005 |
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
Topics: Aniline Compounds; Animals; Anti-Bacterial Agents; DNA Polymerase III; Drug Resistance, Bacterial; G | 2006 |
Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Galactosidase; Coloring Agents; Culture Media; Disin | 2007 |
Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Boronic Acids; Ciprofloxacin; Humans; KB Cells; Multidrug | 2015 |
Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity.
Topics: Animals; Anti-Bacterial Agents; Cornea; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Pos | 2017 |
Anti-Staphylococcal Calopins from Fruiting Bodies of Caloboletus radicans.
Topics: Agaricales; Anti-Bacterial Agents; Cell Line, Tumor; Enterococcus faecalis; Fruiting Bodies, Fungal; | 2018 |
Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.
Topics: Bacterial Infections; Biofilms; Drug Resistance, Multiple; Electron Transport Chain Complex Proteins | 2019 |
Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Survival; Cell Wall; Disease Models, Animal; Methicil | 2021 |
Methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage among patients with diabetes at the Korle Bu Teaching Hospital.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carrier State; Clindamycin; Cross-Sectional Studies; Diabe | 2021 |
Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Carrier Proteins; Ciprofloxacin; Disea | 2021 |
Anti-inflammatory effect, antibiotic potentiating activity against multidrug-resistant strains of Escherichia coli and Staphylococcus aureus, and evaluation of antibiotic resistance mechanisms by the ibuprofen derivative methyl 2-(-4-isobutylphenyl)propan
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Escherichi | 2022 |
ADMET study, spectroscopic characterization and effect of synthetic nitro chalcone in combination with norfloxacin, ciprofloxacin, and ethidium bromide against Staphylococcus aureus efflux pumps.
Topics: Anti-Bacterial Agents; Chalcone; Chalcones; Ciprofloxacin; Ethidium; Humans; Microbial Sensitivity T | 2023 |
Evaluation of the antibacterial and inhibitory activity of NorA and MepA efflux pumps from Staphylococcus aureus by diosgenin.
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Diosgenin; Esc | 2022 |
Injectable Carrier-Free Hydrogel Dressing with Anti-Multidrug-Resistant
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Arginine; Bandages; Humans; Hydrogels; Interleukin- | 2022 |
Inhibition of NorA efflux pump of Staphylococcus aureus by anacardic acids isolated from the cashew nutshell liquid of Anacardium occidentale L.
Topics: Anacardic Acids; Anacardium; Anti-Bacterial Agents; Ethidium; Microbial Sensitivity Tests; Multidrug | 2023 |
In vitro and in silico antibacterial evaluation of coumarin derivatives against MDR strains of Staphylococcus aureus and Escherichia coli.
Topics: Anti-Bacterial Agents; Bacteria; Coumarins; Escherichia coli; Humans; Microbial Sensitivity Tests; N | 2023 |
Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, | 2020 |
Otodectic and bacterial etiology of feline otitis externa in Tripoli, Libya.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Female; Gentamicins; Libya; Male; Mite Infestati | 2021 |
Citral, a monoterpenoid aldehyde interacts synergistically with norfloxacin against methicillin resistant Staphylococcus aureus.
Topics: Acyclic Monoterpenes; Aldehydes; Animals; Anti-Bacterial Agents; Drug Synergism; Methicillin-Resista | 2017 |
Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Topics: Acinetobacter baumannii; Animals; Anti-Bacterial Agents; Biofilms; Carboxylic Acids; Enterobacter; E | 2018 |
Frequency of enterotoxins, toxic shock syndrome toxin-1, and biofilm formation genes in Staphylococcus aureus isolates from cows with mastitis in the Northeast of Brazil.
Topics: Amoxicillin; Animals; Bacterial Toxins; Biofilms; Brazil; Cattle; Enterotoxins; Female; Gentamicins; | 2018 |
Antimicrobial activity of Mimosa caesalpiniifolia Benth and its interaction with antibiotics against Staphylococcus aureus strains overexpressing efflux pump genes.
Topics: Anti-Bacterial Agents; Antiporters; Bacterial Proteins; Candida albicans; Ciprofloxacin; Drug Resist | 2019 |
Usnic acid modifies MRSA drug resistance through down-regulation of proteins involved in peptidoglycan and fatty acid biosynthesis.
Topics: Animals; Anti-Bacterial Agents; Benzofurans; Drug Resistance; Drug Synergism; Fatty Acids; Male; Met | 2019 |
Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Cell Line; Methicillin-Resistant Staphylococcus aureus; Microbial Se | 2019 |
Modulation of the norfloxacin resistance in Staphylococcus aureus by Cordia verbenaceae DC.
Topics: Anti-Bacterial Agents; Cordia; Drug Resistance, Bacterial; Drug Synergism; Hexanes; Humans; Norfloxa | 2013 |
Novel Glycoconjugate of 8-Fluoro Norfloxacin Derivatives as Gentamicin-resistant Staphylococcus aureus Inhibitors: Synthesis and Molecular Modelling Studies.
Topics: Drug Resistance, Bacterial; Gentamicins; Glycoconjugates; Models, Molecular; Norfloxacin; Staphyloco | 2015 |
Sustained release of antibiotic from poly(2-hydroxyethyl methacrylate) to prevent blinding infections after cataract surgery.
Topics: Anti-Bacterial Agents; Deaf-Blind Disorders; Delayed-Action Preparations; Humans; Norfloxacin; Polyh | 2009 |
Norfloxacin and ursolic acid: in vitro association and postantibiotic effect against Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Methicillin Resistance; Microbial Sensitiv | 2011 |
Antifouling foldable acrylic IOLs loaded with norfloxacin by aqueous soaking and by supercritical carbon dioxide technology.
Topics: Acrylamide; Acrylic Resins; Carbon Dioxide; Hydrogels; Lenses, Intraocular; Materials Testing; Metha | 2012 |
In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Methicil | 1994 |
Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus.
Topics: Base Sequence; Humans; Japan; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequenc | 1993 |
In vivo selection during pefloxacin therapy of a mutant of Staphylococcus aureus with two mechanisms of fluoroquinolone resistance.
Topics: Anti-Infective Agents; Bacteriophage Typing; Base Sequence; Drug Resistance, Microbial; Electrophore | 1994 |
[Evolution of fluoroquinolone sensitivity in Staphylococcus aureus isolated from hemocultures in a general hospital].
Topics: Bacteremia; Blood; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hospitals, General; H | 1993 |
Deposits of topical norfloxacin in the treatment of bacterial keratitis.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Chemical Precipitation; Cornea; Corneal Diseases; Cr | 1997 |
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infect | 1998 |
Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
Topics: Anti-Infective Agents; Bacterial Proteins; Biological Transport; Ciprofloxacin; Drug Synergism; Huma | 1999 |
[Combination effect of fosfomycin otic solution and norfloxacin against chronic otitis media].
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Chronic | 1999 |
Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Blood Proteins; Cattle; Chromatography, High Press | 1999 |
The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Drug Interactions; Drug Resistance, Microb | 1999 |
[Studies on pyridonecarboxylic acids as antibacterial agents. XII. Synthesis and antibacterial activity of 6-chloro-1-cyclopropyl-7-(1-piperazinyl)-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid and analogues].
Topics: Animals; Anti-Infective Agents; Carboxylic Acids; Ciprofloxacin; Escherichia coli; Mice; Norfloxacin | 1997 |
[Methicillin-resistant Staphylococcus aureus infection in neutropenic patients during norfloxacin prophylaxis].
Topics: Adult; Fatal Outcome; Female; Humans; Immunocompromised Host; Methicillin Resistance; Middle Aged; N | 1992 |
[Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits].
Topics: Animals; Drug Evaluation; Drug Resistance, Microbial; Male; Norfloxacin; Osteomyelitis; Rabbits; Sta | 1992 |
[Corneal ulcer. Current analysis from specialized ambulatory care of a clinic].
Topics: Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Contact Lenses, Extended-Wear; Corneal | 1992 |
Oral antibiotic prophylaxis in patients with hematological diseases.
Topics: Ciprofloxacin; Humans; Norfloxacin; Sepsis; Staphylococcal Infections | 1991 |
Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.
Topics: Anti-Infective Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Drug Resistance, Microbial; Fluoro | 1991 |
Systemic dry cow therapy--a preliminary report.
Topics: Animals; Cattle; Cephalosporins; Cephapirin; Female; Injections, Intramuscular; Injections, Subcutan | 1990 |
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
Topics: Animals; Chemical Phenomena; Chemistry; Ciprofloxacin; Enterobacter; Enterococcus faecalis; Escheric | 1989 |
The role of quinolones in staphylococcal infection.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Humans; Norfloxacin; Ofloxacin; Pefloxacin; Staphylo | 1989 |
[Passage of pefloxacine into the synovial fluid].
Topics: Anti-Infective Agents; Arthritis, Infectious; Female; Humans; Norfloxacin; Pefloxacin; Staphylococca | 1985 |
Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses.
Topics: Abscess; Administration, Oral; Animals; Anti-Bacterial Agents; Cephalothin; Ciprofloxacin; Injection | 1986 |
[Single day treatment in acute cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cystitis; | 1988 |
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Female; Human | 1988 |
Combination therapy: a way to limit emergence of resistance?
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Resistance, Microbial; Drug Therapy, Com | 1986 |
Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cefaclor; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; | 1985 |
Correlates of therapeutic efficacy in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Topics: Animals; Anti-Infective Agents; Endocarditis, Bacterial; Methicillin; Microbial Sensitivity Tests; N | 1988 |
Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Infective Agents; Endocarditis, Bacterial; Fosfomycin; Male; Methicillin; Norfloxacin; | 1988 |
[Intraocular penetration of pefloxacin in man and rabbit. The aqueous humor and vitreous body].
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Infective Agents; Aqueous Humor; Humans; Middle Aged; | 1987 |
A study of the use of norfloxacin in prostatitis.
Topics: Adult; Escherichia coli Infections; Humans; Male; Norfloxacin; Prostatitis; Staphylococcal Infection | 1987 |
Chemotherapeutic efficacy of ofloxacin on renal and subcutaneous infection models with Staphylococcus aureus in mice.
Topics: Abscess; Animals; Anti-Bacterial Agents; Autoradiography; Disease Models, Animal; Kinetics; Male; Mi | 1986 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
PTFE graft treated with silver norfloxacin (AgNF): drug retention and resistance to bacterial challenge.
Topics: Animals; Anti-Infective Agents; Blood Vessel Prosthesis; Dogs; Escherichia coli Infections; Fluoroqu | 1987 |
[Pefloxacin: clinical experience].
Topics: Acinetobacter Infections; Adult; Aged; Bacterial Infections; Enterobacteriaceae Infections; Enteroco | 1985 |